It has been shown that endogenous ligands or synthetic agonists control the release of insulin in a glucose-dependent way, contrary to insulin, sulfonylureas, and other widely used drugs, having minimal risk of hypoglycemia or other side effects [3,4,5]. This evidence concerns the gene INS and Hypoglycemia.